Search Results for "Dade Behring Pharmaceuticals"
Original Source: Dade Behring Holdings
With 2005 revenue of nearly $1.7 billion, Dade Behring is the world's largest company dedicated solely to clinical diagnostics. It offers a wide range of products, systems and services designed to meet the day-to-day needs of clinical laboratories, delivering innovative solutions to customers and enhancing the quality of life for patients. The businesses from which Dade Behring was formed have been innovators in clinical diagnostics for more than a century. Dade Behring was created in 1997 through the merg...
Matching Channels
None
Matching News
CSL Behring enrolls first patient in global pediatric Phase III pivotal study of recombinant ...
- CSL Behring achieves key milestone in PROLONG-9FP program -- CSL Behring is currently recruiting patients for its Phase III adult and pediatric trials, the final phase of the PROLONG-9FP clinical tr...
CSL Behring bittet um Vorschläge für die dritten Annual Interlaken Leadership Awards
- Globales Programm finanziert innovative Forschung im Bereich Neuroimmunologie King Of Prussia, Pennsylvania (ots/PRNewswire) - CSL Behring engagiert sich dafür, die Lebensqualität von Menschen mi....
CSL Behring launches new dosing app
Biotherapy firm CSL Behring UK has launched an app for doctors to aid the management of its anaesthetic treatment Beriplex P/N. The ‘Dosing Calculator App’ was launched at The General Anaesthetist...
CSL Behring wins FDA nod for Kcentra
The US FDA approved CSL Behring's Kcentra (prothrombin complex concentrate, human) as an urgent reversal treatment for vitamin K antagonist (VKA) anticoagulation in adults with acute major bleeding,...
CSL Behring's hemophilia B treatment enters late-stage development
CSL Behring has started recruitment for a pivotal, late-stage trial of rIX-FPits, a recombinant fusion protein that joins coa -More-
CSL Behring Privigen wins European marketing authorization
CSL Behring's Privigen has obtained marketing authorization from the European Commission for use in chronic inflammatory demyelinating polyneuropathy (CIDP).
CSL Behring gains expanded use for Corifact in USA
Corifact, Factor XIII Concentrate (Human), to include the peri-operative management of surgical bleeding in adult and pediatric patients with congenital factor XIII (FXIII) deficiency. The drug is ma...
FDA approves new vial size for CSL Behring’s Privigen to treat primary immunodeficiency
CSL Behring today announced that the United States Food and Drug Administration has approved a 40 g (400 mL) vial size for Privigen, immune globulin intravenous [human].
Matching PubMed Articles
Correlates of 2009 H1N1 influenza vaccination among day care-aged children, Miami-Dade County.
The aim of this study was to assess factors influencing 2009 H1N1 influenza vaccination among a demographically diverse group of day care-aged children. Day care children were chosen because they were...
Evaluation of a Novel Serology Algorithm to Detect Herpes Simplex Virus 1 or 2 Antibodies.
BACKGROUND:: Herpes simplex virus (HSV)-type specific serology (TSS) testing has been commercially available for nearly a decade. Guidelines on appropriate use of such testing exist, including Canadia...
Reappraisal of MMR Vaccines Currently Used in Korea.
Background: Although MMR vaccine is widely used in Korea, there are limited studies on the currently used vaccines. We evaluated the immunogenicity and safety of MMR vaccines in Korean children. Metho...
Antidepressants at Autopsy in Hispanic Suicidal Youth in Miami-Dade County, Florida*
Controversy has surrounded the use of antidepressants and suicidal behaviors in youth. This study reviewed the Medical Examiner's Office records of 253 persons aged 24 years or younger classifie...
BACKGROUND: Screening and diagnosis of Rubella virus infection rely on testing for specific IgG and IgM. Immunoassays may yield different IgG results especially at low values, with difficulties in the...
